Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Tuesday,Benzinga reports.

A number of other brokerages have also commented on OMER. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

OMER opened at $7.91 on Tuesday. Omeros has a one year low of $2.61 and a one year high of $13.60. The business has a 50 day simple moving average of $8.64 and a two-hundred day simple moving average of $7.61. The firm has a market capitalization of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.03.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC increased its holdings in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new stake in Omeros during the 4th quarter valued at about $46,000. Picton Mahoney Asset Management raised its holdings in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 4,404 shares during the last quarter. Finally, US Bancorp DE bought a new position in shares of Omeros in the fourth quarter worth approximately $81,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.